Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on ENT and allergy patients, announced the granting of non-qualified stock option awards for 54,000 shares to three new employees on April 17, 2023. The stock options, granted outside of the 2010 Stock Incentive Plan, are in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $2.05, matching the closing stock price on the grant date. The options have a 10-year term and will vest over four years, with one-fourth vesting on the first anniversary and the rest in monthly installments, contingent on continued service with the company.

Positive

• Granting stock options to new employees may enhance talent acquisition and retention.
• The exercise price aligns with the market, indicating potential confidence in stock value.

Negative

• Stock options could dilute existing shareholder value if exercised.
• The long vesting period may not immediately benefit investors.

YARDLEY, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 54,000 shares of its common stock to three new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4)

The stock options were granted to the new employees on their hire date April 17, 2023 with an exercise price of $2.05 which is equal to the closing price of the company’s common stock as reported by Nasdaq on the grant date.

The stock options have a 10-year term and vest over four years, with one-fourth of the shares underlying the stock option vesting on the first anniversary of the grant date and the remainder vesting in thirty-six equal monthly installments thereafter. Vesting of the stock options is subject to continued service with the company through the applicable vesting date.

About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531

FAQ

What is the significance of OptiNose granting stock options to employees?

The granting of stock options can attract and retain talent, potentially strengthening the company's workforce.

What does the exercise price of $2.05 for the stock options indicate?

The exercise price of $2.05 reflects the closing stock price on the grant date, which may suggest a stable valuation.

How long is the vesting period for the stock options awarded by OptiNose?

The vesting period for the stock options is four years, with one-fourth vesting after the first year.

What should shareholders know about the stock options granted by OptiNose?

Shareholders should be aware that stock options may lead to dilution of their shares if exercised in the future.